Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › KPRX

Kiora Pharmaceuticals

KPRX Rare disease Lead: Phase 3 7 Biotech Distilled articles ↓ 23 filings & releases ↓ Cash $7.1M (Jun 30, 2026) ↓ 7 verdicts ↓
Ophthalmology Small Molecule

Market cap $6.4M 4.4M shares (10-Q, Aug 5, 2026) × $1.44 close Nov 6, 2026

Most recent annual filing: 2026-01-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Tranche A-1 warrants corporate updateJan 2027Tranche A-1 warrants corporate update, Jan 2027, routine
  2. KIO-401 corporate update2027KIO-401 corporate update, 2027, routine
  3. KIO-301 topline3Q 2027KIO-301 topline, 3Q 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

Ion Channel Modulator

Novel ion channel modulator platform with membrane-calming effects; primary focus on retinal disease (reducing pathological retinal hyperactivity); exploratory expansion into neurological disorders including epilepsy where neuronal hyperexcitability is implicated

Discontinued (2)

Capital (as filed)

Cash
$7.1M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$9.8M Jun 30, 2026
Operating cash flow
−$1.9M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$16.8M cash, runway late 2028 per the update of Oct 29, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (7)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (7 calls)

Every verdict Biotech Distilled has published on Kiora Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-03-09 Watch Kiora Pharmaceuticals (KPRX): Scientific Deep Dive for KIO-301 and Pipeline Products Elegant chemistry with a funded partner removing dilution risk, but N=6 open-label data makes efficacy a coin toss until double-masked ABACUS-2 reads out.
  2. 2026-03-28 Watch UPDATE: Kiora Pharmaceuticals (KPRX) - A 12-Month Delay, a $4.6M Impairment, and the Value of Deep-Pocketed Partners A 12-month delay to Q3 2027 ABACUS-2 data ties up capital longer, but the TOI-funded runway into late 2027 and no forced dilution keep the watch thesis intact.
  3. 2026-04-27 Speculative buy speculative UPDATE: KIORA PHARMACEUTICALS INC (KPRX) - Perceptive Shows Up, Nature Medicine Prints, and the Warrant Structure Tells You the Plan Perceptive's at-market anchor investment, Nature Medicine peer-review validation, runway extension to late 2027 without toxic dilution, and a contractual mandate for a strategic transaction shift the calculus enough to start a position on dips below $2.00.
  4. 2026-08-08 Speculative buy speculative UPDATE: Kiora Pharmaceuticals (KPRX) - The Runway Stretches, and a Catalyst Quietly Moves Up Runway extended to late 2028, ABACUS-2 high-dose cohort underway, and KIO-104 KLARITY readout pulled into late 2026 shorten the wait and improve the setup without changing the core binary risk.
  5. 2026-08-19 Speculative buy speculative UPDATE: Kiora Pharmaceuticals (KPRX) - The Last Map Pin Gets Filled South Korea partnership completes the global commercial map and a coordinated single global Phase 3 is now on record, incrementally strengthening the M&A and partnering thesis while ABACUS-2 remains the central binary.
  6. 2026-09-09 Speculative buy speculative UPDATE: Kiora Pharmaceuticals (KPRX) - They Hired the Phase 3 Guy Hiring a 12-global-Phase-3 veteran as EVP of Global Clinical Development closes the CDO succession gap and signals intent to architect the coordinated global Phase 3, modestly reducing execution risk.
  7. 2026-10-30 Watch UPDATE: Kiora Pharmaceuticals (KPRX) - The Pivot to Eye Stroke In-licensing a self-funded Phase 3 asset (KIO-401) built on a missed primary endpoint, killing the wholly-owned KIO-104 hidden gem, and announcing an unpriced raise destroys the outsourced-cost-risk pillar that underpinned the speculative buy thesis.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (23)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 8, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)